Similarly, dexamethasone had no effect on the expression of mRNA for Gi\g=a\2and Gs\g=a\.
INTRODUCTION
The association between glucocorticoids and hyper¬ tension is well established; for example, more than 70% of patients with Cushing's syndrome are hyper¬ tensive (Plotz et al. 1952; Orth & Liddle, 1971) . Furthermore, hypertension can be induced experi¬ mentally in rats (Knowlton & Loeb, 1957; Krakoff et al. 1975; Haack et al. 1977; Suzuki et al. 1982) and in many other species, using a range of glucocor¬ ticoids including dexamethasone (Suzuki et al. 1982) . Although the mechanisms underlying glucocorticoid hypertension remain to be fully elucidated, a number of glucocorticoid-mediated effects have been implicated; these include increased plasma vol¬ ume (Haack et al. 1977) , stimulation of the reninangiotensin system by increased plasma renin substrate concentration (Krakoff et al. 1975) , decreased prostaglandin synthesis (Handa et al. 1983 ) and enhancement of vascular reactivity to vari¬ ous pressor agents (Mendlowitz et al. 1958; Krakoff et al. 1975; Schomig et al. 1976; Handa et al. 1984; Iijima & Malik, 1985; Whitworth et al. 1986; Russo et al. 1990 ). It is clear, however, that glucocorticoid hypertension is induced through glucocorticoid receptor-dependent mechanisms (Grunfeld et al. 1985) , and glucocorticoid receptors have been iden¬ tified in arterial vessels from a number of species including rats (Meyer & Nichols, 1981) and humans (Scott et al. 1987 ). Post-receptor events, particularly in cultured vascular smooth muscle cells (VSMC), have not been extensively studied. Several intracellular messengers are involved in changes of vascular tone mediated by prostaglandins, vasopressin and a and ß adrenoreceptors, including adenylyl cyclase/ cyclic AMP (cAMP), the inositol phosphates and cyclic GMP. Dexamethasone administration in vitro has been shown to increase adenylyl cyclase activity in VSMC from renal arteries (Yasunari et al. 1989) , and similar observations have been made in a number of non-vascular cell lines (Foster & Perkins, 1977; Johnson & Jaworski, 1983; Rizzoli et al. 1986 ; Rodan & Rodan, 1986; Chang & Bourne, 1987 (Rodan & Rodan, 1986; Chang & Bourne, 1987) and in vivo (Haigh et al. 1990 ). Increases in Gso (Rodan & Rodan, 1986; Chang & Bourne, 1987) , with either no change (Chang & Bourne, 1987) or an increase (Rodan & Rodan, 1986) (1977) .
The purity of the plasma membrane preparations was assessed by measuring 5' nucleotidase (EC 3.1.3.5) activity (Dixon & Purdom, 1954 (Salomon, 1979 (Laemmli, 1970) and boiled for 3 min before resolution by SDS- polyacrylamide gel electrophoresis (PAGE) on gels containing 10% acrylamide and 0-8% N,N'-bismethylene acrylamide. Immunoblotting with anti-peptide antisera was then performed as detailed previously (Gawler et al. 1987; Bushfield et al. 1990a ). Briefly, proteins were transferred to nitrocellulose paper (Towbin et al. 1979 ) which was then blocked for 2 h in 5% dried skimmed milk in buffer comprising 50 mM NaCl in 20 mM Tris-HCl (pH 7-5). After washing, the blot was incubated at 37°C overnight with antiserum (at a 1: 200 dilution in 1% gelatin in phosphate-buffered saline). Follow¬ ing a further wash, the blot was then incubated for 2 h with the second antibody (horseradish peroxidase-labelled donkey anti-rabbit IgG or I-labelled anti-rabbit IgG). The peroxidase-labelled bands were visualized with o-dianisidine (Milligan et (Foster & Perkins, 1977; Johnson & Jaworski, 1983; Rizzoli et al. 1986 ; Rodan & Rodan, 1986; Chang & Bourne, 1987; Yasunari et al. 1989 ). However, the extent of glucocorticoid enhancement of adenylyl cyclase activity in these other studies varied widely from 17% (Rizzoli et al. 1986 ) to 2000% (Yasunari et al. 1989 ). (Foster & Perkins, 1977; Johnson & Jaworski, 1983; Rizzoli et al. 1986; Chang & Bourne, 1987; Yasunari et al. 1989) (Mano et al. 1979 ; Davies & Lefkowitz, 1980; Fraser & Venter, 1980 (Davies & Lefkowitz, 1980) . The potentiation of the renal effects of vasopressin by adrenocortical steroids (Jackson et al. 1983) has been attributed to an inhibition of cAMP-dependent phosphodiesterase activity. Similarly, testicular and myocardial phosphodiesterases are inhibited by glucocorticoids (Manganiello & Vaughan, 1973; Schmidtke et al. 1976 ; Chen & Feldman, 1978 
